TCON TRACON Pharmaceuticals, Inc.

4.30
0  -1%
Previous Close 4.35
Open 4.30
Price To book 2.47
Market Cap 69.50M
Shares 16,163,000
Volume 22,218
Short Ratio 2.63
Av. Daily Volume 81,168

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing to be initiated 1H 2017.
TRC253
Prostate cancer
Phase 2 trial to be initiated in 2017.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with data due early 2018.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 4Q 2017.
TRC105
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2017.
TRC102
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 data due late 2016 according to 10Q filed November 2016. As of January 9, 2016, data have not been released and no mention of the trial was made in its January 9 presentation.
TRC105
Soft tissue sarcomas

Latest News

  1. TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  2. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
  3. TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
  4. TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  5. TRACON PHARMACEUTICALS, INC. Financials
  6. TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference
  7. Edited Transcript of TCON earnings conference call or presentation 28-Feb-17 9:30pm GMT
  8. TRACON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
  9. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
  10. Tracon reports 4Q loss
  11. Tracon reports 4Q loss
  12. TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
  13. Q4 2016 TRACON Pharmaceuticals Inc Earnings Release - After Market Close
  14. TRACON to Report Fourth Quarter and Full Year 2016 Company Highlights and Financial Results on February 28, 2017
  15. TRACON Pharmaceuticals Announces First Patient Dosed in Phase 3 TAPPAS Trial of TRC105 in Angiosarcoma
  16. Tracon Pharma Tanks on Brain Cancer Drug Failure
  17. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. TRACON Pharmaceuticals Announces Top-line Results from NCI-Sponsored Phase 2 Trial of TRC105 in Recurrent Glioblastoma
  19. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  20. TRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin